8Newman-Tancredi A, Heusler P, Martel J C, et al. Agonist and antagonist properties of antipsychotics at human dopamine D4. 4 receptors: G-protein activation and K channel modulation in transfected cells [ J ]. Int J Neuropsychopharmacol,2007,26( 1 ) :1-15.
9Tadori Y, Kitagawa H, Forbes R A, et al. Differences in agonist/antagonist properties at human dopamine D (2) receptors between aripiprazole, bifeprunox and SDZ 208-912 [ J ]. Eur J Pharmacol,2007,28 ( 3 ) : 103-121.
10Bruins Slot L A, Palmier C, Tardif S, et al. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation [ J ]. Neuropharmacology, 2007,53 ( 1 ) :232-241.
7NORMAN SARTORIUS,W FLEISCHHACKER,ANNETTEGJIE RNS,et al.The usefulness and use of second generation antipsychotic medications [J].Current Opinion in Psychiatry,2002,3 (9):15.
8GEDDES J,FREEMANTLE N,HARRISON P,et al.Atypical antipsychotics in the treatment of schizophrenia:systematic overview and metaregression analysis [J ].Br Med J,2000,32 (1) :1371-2000.
9FELDMAN PD,KAISER CJ,KENNEDY JS,et al.Comparison of risperidoneand olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years[J].Clin Psychiatry,2003,64(9):9981.
